OncoMatch/Clinical Trials/NCT07025018

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Is NCT07025018 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HMPL-306 for gliomas harboring idh1 and/or idh2 mutations.

Phase 1RecruitingHutchmedNCT07025018Data as of May 2026

Treatment: HMPL-306 — This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: IDH1 mutation

Required: IDH2 mutation

Prior therapy

Cannot have received: IDH inhibitor

Previous treatment with IDH inhibitors

Lab requirements

Blood counts

Sufficient bone marrow and organ function

Kidney function

Sufficient bone marrow and organ function

Liver function

Sufficient bone marrow and organ function; history of clinically significant liver disease, including active infection with viral hepatitis, or other active hepatitis, alcoholic liver disease, cirrhosis, etc. [excluded]

Sufficient bone marrow and organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify